Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
News
Sports
TV & Film
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/04/e1/22/04e122ab-a12d-c183-2d35-1cae1373c023/mza_6262719269478151817.jpg/600x600bb.jpg
iForumRx.org
University of Mississippi School of Pharmacy
100 episodes
1 week ago
This is the podcast site for iForumRx.org - a community of ambulatory care pharmacy specialists and others interested in the evidence regarding drug therapy and patient management.
Show more...
Medicine
Health & Fitness
RSS
All content for iForumRx.org is the property of University of Mississippi School of Pharmacy and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This is the podcast site for iForumRx.org - a community of ambulatory care pharmacy specialists and others interested in the evidence regarding drug therapy and patient management.
Show more...
Medicine
Health & Fitness
https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/04/e1/22/04e122ab-a12d-c183-2d35-1cae1373c023/mza_6262719269478151817.jpg/600x600bb.jpg
A Broken Heart: Empagliflozin Falls Flat after Acute Myocardial Infarction
iForumRx.org
20 minutes 33 seconds
1 year ago
A Broken Heart: Empagliflozin Falls Flat after Acute Myocardial Infarction
Despite advances in the management of acute myocardial infarction (MI), up to 38% of patients will experience signs of heart failure (HF) and many have a reduced left ventricular ejection fraction (LVEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented cardiovascular benefits. However, data are limited regarding their use after an acute MI. Guest Authors: Amy Hu, PharmD and Kathleen Pincus, PharmD, BCPS, BCACP, CDCES Music by Good Talk
iForumRx.org
This is the podcast site for iForumRx.org - a community of ambulatory care pharmacy specialists and others interested in the evidence regarding drug therapy and patient management.